buyWeak cluster of 2
Johan Wedell-Wedellsborg bought $44k of YMAB
director at Y-mAbs Therapeutics, Inc.. 6,455 shares at an average of $6.85, traded Dec 11, 2023, filed Dec 12, 2023.
Conviction score
29Value
$44k
6,455 shares
Holdings after
4,559,233
+0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +6Trade size$44k at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying4 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-23-125199, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2023 | POpen-market purchase Common Stockindirect: By WG Biotech ApS | +6,455 | $6.85 | $44k | 4,559,233 | Dec 12, 2023 |
Related signals
Other insiders at Y-mAbs Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $57k 10,810 shares | -5% | |
| 33Weak | Y-mAbs Therapeutics, Inc. | Gerard Ber director | $8,664 722 shares | -31% | |
| 56Moderate | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $841k 70,000 shares | -30% | |
| 36Weak | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $396k 32,351 shares | -12% | |
| 38Weak | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $64k 3,900 shares | -2% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Vignesh Rajah SVP & CHIEF MEDICAL OFFICER | $28k 1,711 shares | -5% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER | $28k 1,682 shares | -5% | |
| 50Moderate | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad Chief Business Officer | $1.0M 150,000 shares | -36% | |
| 29Weak | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $44k 6,455 shares | +0% | |
| 51Moderate | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $890k 127,549 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.